Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 11:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 13,953 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: combined treatment Clear all
Completed Phase 2 Interventional Results available

A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

NCT00869791
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, IR CD-LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Not applicable Interventional

Collaborative Adolescent Research on Emotions and Suicide

NCT01528020
View directory record Official record
Conditions
Suicidal and Self-injurious Behaviour
Interventions
Dialectical Behavior Therapy, Individual and Group Supportive Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
13 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 12, 2026, 11:32 PM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography with Contrast, Eribulin Mesylate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 12, 2026, 11:32 PM EDT
Recruiting Phase 2 Interventional

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

NCT05588388
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer, Liver Metastases
Interventions
Bevacizumab
Drug
Lead sponsor
Kamya Sankar
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT00989586
View directory record Official record
Conditions
Lymphoma
Interventions
milatuzumab, veltuzumab, Correlative/Special Studies, Quantitative T-, B-, and NK cell subsets, Pharmacokinetics, Human Anti-Human Antibodies, veltuzumab and milatuzumab
Biological · Procedure
Lead sponsor
Beth Christian
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Phase 1 Interventional

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

NCT00598169
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
Biological · Drug · Genetic
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 12, 2026, 11:32 PM EDT
Active, not recruiting Not applicable Interventional

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

NCT01918683
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Maywood, Illinois • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Phase 2 Interventional Results available

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

NCT02794883
View directory record Official record
Conditions
Malignant Glioma, Recurrent Glioblastoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Surgical Procedure, Tremelimumab
Biological · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 12, 2026, 11:32 PM EDT
Recruiting Phase 1 Interventional

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

NCT05714072
View directory record Official record
Conditions
Myelofibrosis Due to and Following Polycythemia Vera
Interventions
Ruxolitinib, Abemaciclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 12, 2026, 11:32 PM EDT
Recruiting Phase 1 Interventional

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

NCT06663072
View directory record Official record
Conditions
Metastatic Pancreatic Neuroendocrine Tumor
Interventions
Fulvestrant, 177Lu-DOTATATE
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00487669
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
paclitaxel poliglumex, pemetrexed
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of the Role of 905-nm Laser Light in the Delay of Muscle Fatigue

NCT03461731
View directory record Official record
Conditions
Muscle Fatigue
Interventions
Control, 800 nm laser, combination laser, 905 nm laser
Device
Lead sponsor
College of Charleston
Other
Eligibility
18 Years to 25 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 12, 2026, 11:32 PM EDT
Not listed Phase 2 Interventional

Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery

NCT00251329
View directory record Official record
Conditions
Breast Cancer
Interventions
neoadjuvant chemotherapy
Drug
Lead sponsor
Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
6
States / cities
Jacksonville, Florida • Lakeland, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Phase 1 Interventional

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

NCT00633529
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
IMO-2055
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Ocoee, Florida • Indianapolis, Indiana • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Oct 12, 2026, 11:32 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

NCT02755272
View directory record Official record
Conditions
Carcinoma Breast Stage IV
Interventions
Pembrolizumab, Carboplatin, Gemcitabine
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
6
States / cities
Indianapolis, Indiana • St Louis, Missouri • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 12, 2026, 11:32 PM EDT
Recruiting Not applicable Interventional

Arterial Stiffness and Blood Pressure

NCT06495710
View directory record Official record
Conditions
Hypertension, Vascular Stiffness, Aging
Interventions
Blood pressure treatment algorithm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 12, 2026, 11:32 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Project AWARE: Using the Emergency Department (ED) to Prevent Sexually Transmitted Infections (STIs) in Youth

NCT01195220
View directory record Official record
Conditions
Chlamydia, Gonorrhea, HIV
Interventions
HIV testing, STI/HIV-T, STI/HIV-Plus
Behavioral
Lead sponsor
North Bronx Healthcare Network
Other
Eligibility
14 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Phase 2 Interventional Results available

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

NCT00069160
View directory record Official record
Conditions
Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
Interventions
docetaxel, tariquidar, 99mTc-sestamibi imaging
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 12, 2026, 11:32 PM EDT
Terminated Phase 1 Interventional

Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01701323
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia
Interventions
Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion, Cytarabine, Filgrastim, Fludarabine Phosphate
Biological · Drug
Lead sponsor
Nohla Therapeutics, Inc.
Industry
Eligibility
6 Months to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 12, 2026, 11:32 PM EDT
Completed Phase 1 Interventional

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

NCT01276496
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 12, 2026, 11:32 PM EDT
Terminated Phase 2 Interventional Results available

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

NCT04272242
View directory record Official record
Conditions
HIV Infection, LTBI
Interventions
Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT), Antiretroviral Therapy (ART), Pyridoxine (Vitamin B6)
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 12, 2026, 11:32 PM EDT
Not listed Phase 1 Interventional

Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer

NCT00004173
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oxaliplatin, paclitaxel
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 12, 2026, 11:32 PM EDT